Skip to Content

Inhibitex to Present at Two Upcoming Conferences

ATLANTA--(BUSINESS WIRE)--Mar 8, 2010 - Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following two conferences:




  • Roth Capital Partners 22nd Annual OC Growth Stock Conference on Tuesday, March 16, 2010 at the Ritz Carlton in Dana Point, California. In addition, Dr. Joseph Patti, Senior Vice President of Research and Development and Chief Scientific Officer, will be participating in a panel discussion at the conference on that same day entitled: “Antivirals – New Solutions to Old Problems.”
  • Canaccord Adams Hepatitis C Conference on Thursday, April 1, 2010 at The Peninsula Hotel in New York City, New York.


About Inhibitex


Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company's pipeline includes FV-100, which is in Phase II clinical development, for the treatment of shingles and INX-189, a nucleotide polymerase inhibitor for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development, and has licensed the use of its proprietary MSCRAMM® protein technology to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit


Inhibitex® and MSCRAMM® are registered trademark of Inhibitex, Inc.





Contact: Inhibitex, Inc.

Russell H. Plumb, 678-746-1136

Chief Executive Officer



Posted: March 2010